Pharmaceutical management of hepatitis B and C in liver and kidney transplant recipients

doi:10.4292/wjgpt.v6.i4.105

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 6, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8933)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-2) series.

Item

Count

PDF

468

WORD

309

HTML

3267

Tables (1-2)

246

Sum=4290

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

555

Download

1306

Sum=1861

Publishing Process of This Article

Item

Count

Browse

1252

Download

1530

Sum=2782

Nov 6, 2015 (publication date) through Jan 18, 2025

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Pharmacology and Therapeutics

ISSN

2150-5349

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Gastrointest Pharmacol Ther. Nov 6, 2015; 6(4): 105-110
Published online Nov 6, 2015. doi: 10.4292/wjgpt.v6.i4.105

Table 1 Recommendations for the management of hepatitis B and C infection after liver or kidney transplantation

Chronic hepatitis B	Post-liver transplantation	Prophylaxis and treatment	HBIG (for short term) plus NA¹
	Post-kidney transplantation		NAs¹
Chronic hepatitis C	Post-liver transplantation	No prophylaxis	Sofosbuvir based regimens or “3D” regimen plus RBV (for genotypes 1 and 4)
	Post-kidney transplantation		Newer direct oral antivirals plus/minus RBV (studies are ongoing)²

¹Frontline analogues are considered entecavir or tenofovir in renal proper doses (consider telbivudine in the presence of renal dysfunction);

²Interferon is contraindicated due to the high risk of allograft rejection. HBIG: Hepatitis B immune globulin; NAs: Nucleos(t)ide analogues; 3D: Paritaprevir (plus ritonavir)/ombitasvir/dasabuvir for genotype 1 and paritaprevir (plus ritonavir)/ombitasvir for genotype 4; RBV: Ribavirin.

Citation: Pipili C, Cholongitas E. Pharmaceutical management of hepatitis B and C in liver and kidney transplant recipients. World J Gastrointest Pharmacol Ther 2015; 6(4): 105-110
URL: https://www.wjgnet.com/2150-5349/full/v6/i4/105.htm
DOI: https://dx.doi.org/10.4292/wjgpt.v6.i4.105